Duchenne Breakthrough Hopes Rise With More Data From Sarepta Gene Therapy

Phase II Data Bodes Well For Pivotal EMBARK Trial

 
• By Andrew McConaghie

More data from Sarepta’s mid-stage studies help bolster confidence in the gene therapy but will the US FDA call in the drug for an early appraisal or await Phase III data next year?

Sarepta building
Sarepta expect to complete dosing in their Phase III EMBARK study later this year, with a first readout then due in mid-2023 • Source: Shutterstock

More from Business

More from Scrip